Appeals Court Rejects Challenge To Alpharma's 180-Day Exclusivity For Pfizer's Neurontin
In its decision, the court held that Apotex could have raised the challenge in an earlier litigation among the same parties, but failed to do so.
The court also vacated a related lower court’s decision upon which Apotex’s challenge was based. A similar challenge to Alpharma gabapentin exclusivity by Ivax Corporation remains before...
To view the full article, register now.